Journal article
Efficacy of Australian red-back spider (Latrodectus hasselti) antivenom in the treatment of clinical envenomation by the cupboard spider Steatoda capensis (Theridiidae)
BU Atakuziev, CE Wright, A Graudins, GM Nicholson, KD Winkel
Toxicon | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2014
Abstract
We describe the first Steatoda capensis envenomation treated with CSL red-back spider antivenom (RBSAV). The patient, a 51-year-old female, developed acute local pain, swelling, redness, and diaphoresis in association with tender lymphadenopathy and hypertension. These features responded, in a dose-dependent manner, to RBSAV. In vitro studies confirmed that RBSAV could neutralize S. capensis venom at equivalent concentrations required to neutralize red-back spider (Latrodectus hasselti) venom. Similar data were obtained using Mexican Latrodectus mactans antivenom (Aracmyn®). Although S. capensis yielded similar quantities of venom protein as L. hasselti, pooled S. capensis and Steatoda gross..
View full abstractGrants
Funding Acknowledgements
The authors wish to thank Mr Mark Ross-Smith (University of Melbourne) for assistance with the myograph experiments; Dr Mark Harvey, WA Museum, Mr David Hirst, SA Museum, Dr Robert Raven, Queensland Museum and Ms Catriona McPhee, Museum of Victoria, for spider identification; Mr Pat Honan, formerly of Melbourne Zoo, for beetle identification; Dr Peter Wirth, formerly of the Ballarat Base Hospital, for clinical details; Dr Jorge Paniagua-Solis, (Laboratorios Silanes, SA de CV, Toluca, DF, Mexico), for provision of Mexican (Aracmyn) antivenom; Associate Professor James Tibballs for translation assistance and the University of Melbourne Visiting Research Scholars Scheme for support to Dr Bakhadir Atakuziev. Dr Andis Graudins was supported by an APA scholarship and Dr Ken Winkel is supported by a direct grant from the Australian Government through the National Health and Medical Research Council.